These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12737118)

  • 21. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
    Sukasem C; Churdboonchart V; Chasombat S; Kohreanudom S; Watitpun C; Pasomsub E; Piroj W; Tiensuwan M; Chantratita W
    Infection; 2007 Apr; 35(2):81-8. PubMed ID: 17401711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005].
    Afani S A; Orellana R L; Duarte J P; Acevedo M W; Morales B O; Wolff R M; Vásquez P; Beltrán C
    Rev Med Chil; 2007 Oct; 135(10):1237-44. PubMed ID: 18180829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Future implications: compliance and failure with antiretroviral treatment.
    Patel AK; Patel KK
    J Postgrad Med; 2006; 52(3):197-200. PubMed ID: 16855321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
    Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
    HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
    Canestri A; Ghosn J; Wirden M; Marguet F; Ktorza N; Boubezari I; Dominguez S; Bossi P; Caumes E; Calvez V; Katlama C
    Antivir Ther; 2006; 11(5):561-6. PubMed ID: 16964823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
    Prado JG; Parkin NT; Clotet B; Ruiz L; Martinez-Picado J
    Clin Infect Dis; 2005 Sep; 41(5):729-37. PubMed ID: 16080097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges of the unmet needs in the treatment-experienced patient.
    Montaner JS
    AIDS Read; 2003 Jun; 13(6 Suppl):S5-9. PubMed ID: 12838741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Genotypic antiretroviral resistance testing and phylogenetic analysis of protease and reverse transcriptase in antiretroviral drug-naïve AIDS patients in Henan province].
    Yang K; Li JY; Bao ZY; Li HP; Li L; Zhuang DM; Wang Z; Li H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 May; 26(5):351-5. PubMed ID: 16053762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment strategies for highly treatment-experienced HIV-infected patients.
    Luber AD
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):815-23. PubMed ID: 16207173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The risks and incidence of K65R and L74V mutations and subsequent virologic responses.
    Waters L; Nelson M; Mandalia S; Bower M; Powles T; Gazzard B; Stebbing J
    Clin Infect Dis; 2008 Jan; 46(1):96-100. PubMed ID: 18171220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current concepts in antiretroviral therapy failure.
    del Rio C
    Top HIV Med; 2006; 14(3):102-6. PubMed ID: 16946454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.